Views 1,066
Citations 0
Research Letter
December 2015

Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors

Author Affiliations
  • 1Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2015;175(12):1990-1992. doi:10.1001/jamainternmed.2015.5396

An association between usage of tumor necrosis factor inhibitors (anti-TNF) in patients with inflammatory bowel disease (IBD) and other immune-mediated diseases and demyelinating diseases in the central nervous system has been suggested by case reports.1,2 However, it remains uncertain whether these cases are directly related to anti-TNF therapy because there is evidence of an underlying association between demyelinating disease and IBD.3 In a nationwide population-based cohort, we compared rates of central demyelinating diseases among patients with IBD exposed and unexposed to anti-TNF.

First Page Preview View Large
First page PDF preview
First page PDF preview